Compare CVS Health Corp (CVS) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Oxford Lane Capital Corp — how do they compare? CVS Health Corp trades at $93.65 (market cap $122.36B), while Oxford Lane Capital Corp trades at $9.34 (market cap $905.21M). The key difference: CVS Health Corp is far larger — about 135.2× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.89%). Which is the better fit depends on your goals.
| CVS | OXLC | |
|---|---|---|
Market Cap | $122.36B | $905.21M |
Sector | Health | Financials |
52-Week High | $110.60 | $18.75 |
52-Week Low | $65.51 | $8.15 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | 25.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
OXLC trades at $9.20, up 0.44% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock's valuation shows a low price-to-book ratio of 0.88, yet profitability metrics are deeply negative with an ROE of -39.16%. Recent earnings have consistently missed expectations, and the company has declared a series of $0.20 dividends through 2026. Cash flow from operations was negative $703.80M in 2025, offset by financing activities.
The outlook is clouded by severe fundamental deterioration, including a projected revenue collapse and net loss for 2026. While the high dividend yield and discounted P/B may attract some investors, the risks from unsustainable distributions, declining net asset value, and negative returns on equity warrant extreme caution. Analyst sentiment is mixed, reflecting the stock's high-risk, high-yield profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
